Status:

RECRUITING

The Effectiveness of Written Exposure Therapy for PTSD

Lead Sponsor:

Peking University

Conditions:

PTSD

Subclinical PTSD

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Study 1: The goal of this study is to use a pilot RCT to assess the effectiveness of Written Exposure Therapy (WET) and a mindfulness-based app (MBA) for managing PTSD and comorbid insomnia in China. ...

Eligibility Criteria

Inclusion

  • Study 1:
  • Adult male and female aged between 18-65 years old; A diagnosis of PTSD or subthreshold PTSD (PTSD Symptom Scale, Interview Version for DSM-5, PSSI-5); If currently taking psychotropic medication, taking a stable one for at least 4 weeks; A smartphone owner and no obstacle to the Now Meditation App; Scoring 12 or more on Insomnia Severity Index (ISI; the symptoms appear after the diagnosis of full/subthreshold PTSD).

Exclusion

  • A diagnosis of bipolar disorder or psychotic disorder; Current substance dependence; Evidence of a moderate or severe traumatic brain injury (as determined by the obstacle to comprehending the baseline screening questionnaires); Serious suicidal ideation (as determined by the Scale for Suicidal Ideation); Other psychiatric disorders severe enough to warrant designation as the primary disorder; Taking psychotherapy for PTSD currently.
  • Study 2:
  • Inclusion Criteria:
  • Adult male and female (aged between 18-65 years old)
  • A diagnosis of PTSD or subclinical PTSD (PTSD Symptom Scale, Interview Version for DSM-5, PSSI-5), meeting the following criteria: Meeting full criteria for re-experiencing and at least 2 of 3 other symptom clusters (i.e., avoidance, negative cognitions, or hyperarousal)
  • If currently taking psychotropic medication, taking a stable one for at least 4 weeks
  • Having the ability to write and comprehend the writing guidelines

Key Trial Info

Start Date :

June 15 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 10 2024

Estimated Enrollment :

135 Patients enrolled

Trial Details

Trial ID

NCT05421494

Start Date

June 15 2022

End Date

December 10 2024

Last Update

October 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University

Beijing, Beijing Municipality, China, 100871